Scienture Holdings Enhances Healthcare Access with New Agreements
Signifying a potential reach into about 20% of the U.S. institutional market, Scienture Holdings, Inc. (NASDAQ: SCNX) is paving the way for Arbli™ (losartan potassium) across a range of healthcare facilities.
The U.S. losartan market, valued at $256 million annually, witnesses around 71 million prescriptions. This presents a robust opportunity for Arbli™, recognized as the first FDA-approved ready-to-use oral suspension formulation of losartan.
Scienture, headquartered in Commack, NY, has officially entered into multiple commercial group purchasing organization (GPO) agreements for its product, Arbli™ (losartan potassium) Oral Suspension, 10 mg/mL. This development grants access to over 2500 healthcare institutions, such as hospitals, clinics, nursing homes, specialty pharmacies, long-term care facilities, and ambulatory centers. Such broad accessibility indicates an estimated penetration into roughly 20% of the U.S. institutional market while broadening the product’s reach across various long-term care and outpatient settings.
"The signing of these GPO agreements marks a crucial achievement for Scienture and for Arbli™," expressed Narasimhan Mani, President and co-CEO of Scienture. "This access positions Arbli™ to cater to the patients and healthcare providers who need it the most. We are dedicated to further expanding partnerships and direct contracts to enhance our presence in the institutional market nationwide, showing our firm commitment to creating substantial growth opportunities and long-term value for our stakeholders."
Arbli™ is an innovative proprietary formulation of losartan, a commonly prescribed angiotensin receptor blocker (ARB) used for treating hypertension. Notably, it is the first and only liquid formulation of losartan readily available, eliminating the need for compounding. Arbli™ features a reduced dosing volume and the capability of being stored at room temperature for an extended period, showcasing a significant advancement in patient compliance.
FDA-approved for treating hypertension in patients aged six years and older, Arbli™ also aids in lowering the risk of stroke in patients experiencing hypertension accompanied by left ventricular hypertrophy and aids individuals with diabetic nephropathy linked to type 2 diabetes. By producing a reliable and effective liquid alternative, Arbli™ addresses the unique needs of patients who favor or require a liquid formulation.
This ready-to-use formulation spells a noteworthy advancement as it guarantees quality and dosing precision. It effectively mitigates the concerns surrounding traditional compounded losartan prescriptions, which may often be inconsistent in quality.
According to IQVIA data for the most recent fiscal period, the U.S. market for losartan is estimated to generate $256 million in sales with a total of 71 million prescriptions being dispensed. Presently, all competing losartan products in the market are offered solely in oral solid form.
Shankar Hariharan, Executive Chairman and co-CEO of Scienture, stated, "GPO agreements serve as a critical access pathway. Once listed, products become swiftly available to member institutions, allowing for a rapid adoption rate without needing to create individual agreements anew. This aspect underscores a significant opportunity for Arbli™ as it stands out as the first FDA-approved, ready-to-use oral suspension formulation."
Understanding Arbli
Arbli™ stands prominent as the exclusive oral liquid formulation of losartan that has gained U.S. FDA approval. This peppermint-flavored suspension is presented in a 165 mL bottle, requires no refrigeration, and has a shelf life extending to 24 months from the manufacturing date when stored at room temperature.
Indications for Use
Arbli™ is utilized as an angiotensin II receptor blocker (ARB) indicated for:
- Managing hypertension to effectively reduce blood pressure in patients aged six years and older.
- Lowering the risk of stroke in patients with coexisting hypertension and left ventricular hypertrophy.
- Treating diabetic nephropathy in individuals with type 2 diabetes and associated hypertension, as demonstrated by elevated serum creatinine and proteinuria levels.
Crucial Safety Information
Patients should refrain from taking Arbli™ during pregnancy due to potential fetal harm. Continual use after pregnancy detection should cease immediately, as medications targeting the renin-angiotensin system pose risk to fetal health. Additionally, concurrent use of Arbli™ with aliskiren in diabetic patients should be avoided, alongside patients with severe hepatic impairment, as the effects remain untested in such populations. Common side effects with an incidence of 2% or greater than placebo include dizziness, upper respiratory infections, nasal congestion, and back pain.
About Scienture Holdings, Inc.
SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) functions through its subsidiary, Scienture, LLC, a holistic pharmaceutical company focused on delivering enhanced value to patients, physicians, and caregivers. The company specializes in developing and deploying innovative specialty products to meet unfulfilled market demands. Scienture's focus spans various therapeutic areas, presenting unique products to cater to diverse market segments and healthcare channels. To learn more, reach out to SCIENTURE HOLDINGS, INC., located at 20 Austin Blvd, Commack, NY 11725. For inquiries, call (866) 468-6535 or email IR@Scienture.com.
Frequently Asked Questions
What is Arbli™?
Arbli™ is the first FDA-approved ready-to-use oral suspension of losartan potassium, designed for patients requiring liquid medication.
How does Arbli™ benefit patients?
Arbli™ offers a safe and reliable alternative to compounded losartan, ensuring accurate dosing and improved patient compliance.
What recent agreements has Scienture established?
Scienture has signed agreements with multiple group purchasing organizations, providing Arbli™ access to over 2500 healthcare institutions.
What is the market potential for Arbli™?
Arbli™ targets approximately 20% of the U.S. institutional market, tapping into an estimated $256 million annual market for losartan.
How can I reach Scienture for more information?
For further details, you can call Scienture Holdings, Inc. at (866) 468-6535 or email them at IR@Scienture.com.
